Article
Etranacogene dezaparvovec for hemophilia B gene therapy
1 Jan 2021
Abstract excerpt
The treatment landscape for hemophilia has been rapidly changing with introduction of novel therapies. Gene therapy for hemophilia is a promising therapeutic option for sustained endogenous factor production to mitigate the need for prophylactic treatment to prevent spontaneous and traumatic bleeding. Etranacogene dezaparvovec is an investigational factor IX (FIX) gene transfer product that utilizes the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
